Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Two loss years in a row NBB
Negative result in 2024 and 2025.
Financials
Financial year 2025
IKRIS PHARMA INTERNATIONAL from Dison, company number BE0642608172, closed financial year 2025 with a result of € -10,483 after tax. For that financial year IKRIS PHARMA INTERNATIONAL recorded a gross margin of € -7,103 and equity of € 63,628. Compared with financial year 2024, the result moved from € -19,877 to € -10,483. The company made a loss. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 17, 2026.
€ 63,628
▼ 14% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -10,483
▲ 47 % less loss than in 2024
Profit after tax over the fiscal year.
€ 74,566
▼ 32% vs 2024
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € 43,628.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 76,398
▲ 57% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 213
Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 156,984 | € 6,666 | € 53,327 | € -7,103 | ▼ € 60,430 |
| Profit after taxes | € 13,252 | € -2,060 | € -19,877 | € -10,483 | ▲ € 9,394 |
| Equity | € 96,048 | € 93,988 | € 74,111 | € 63,628 | ▼ 14% |
| Total debts | € 445,095 | € 258,273 | € 92,069 | € 87,411 | ▼ 5% |
| Cash | € 125,467 | € 137,251 | € 110,357 | € 74,566 | ▼ 32% |
| Retained profit | € 76,048 | € 73,988 | € 54,111 | € 43,628 | ▼ 19% |
| Balance sheet total | € 541,142 | € 352,261 | € 166,179 | € 151,039 | ▼ 9% |
Key figures of IKRIS PHARMA INTERNATIONAL, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to IKRIS PHARMA INTERNATIONAL?
What happened at IKRIS PHARMA INTERNATIONAL in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: loss of € 10,483. Source: NBB ↗
- New establishment in Bassenge. KBO
- Start of the company according to the CBE. KBO
In short
From € 13,252 profit in 2022 to € 10,483 loss in 2025.
Paid € 4,821 in corporate taxes since 2022.
Best year ever: 2022, with € 13,252 profit.
A new publication or filing at IKRIS PHARMA INTERNATIONAL? We notify you, reason included.
Follow IKRIS PHARMA INTERNATIONALDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
The stake of BELDIMED comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
IKRIS PHARMA INTERNATIONALBehind IKRIS PHARMA INTERNATIONAL are Philipp Gertrude Quodbach and Parveen Kurner Sikri. The shares are held by BELDIMED (50%).
Establishments
Establishment units
Physical locations of this company
Rue Zénobe Gramme 39
4821 Dison
Rue Marcel de Brogniez 27 box 1
4690 Bassenge
Active since 3 November 2015
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 6 companies are registered at this address.
All companies at this address →BELDIMED same network
€ 789,471 gross margin · 2025
POP N PLAY
FAMILIA
€ 255,041 gross margin · 2025
OLSEN ENGINEERING
€ 3.3 million gross margin · 2024
Link Office
€ 2,624 gross margin · 2024
+1 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0642.608.172
- VAT number
- BE 0642.608.172
- Registered office
- Rue Zénobe Gramme 39, 4821 Dison
- Names & denominations
- IKRIS PHARMA INTERNATIONAL
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 3 November 2015
- Peppol
- Active · Active since 10 Mar 2026
- Activities · NACE
Groothandel in farmaceutische en medische artikelen